Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atu027
- Development stage
- Phase 2
- Lead developer
- Silence Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Atu027 is a novel investigational RNA interference (RNAi) therapeutic designed to silence the expression of protein kinase N3 (PKN3) in the vascular endothelium. It consists of a chemically stabilized short-interfering RNA (siRNA) encapsulated in cationic and fusogenic lipids, forming a lipoplexed formulation. PKN3 acts as a downstream effector in the PI3K signaling pathway and is implicated in cellular morphology, locomotion, tumor progression, and metastasis formation. By targeting PKN3 mRNA via RNA interference, Atu027 inhibits local tumor invasion as well as lymph node and pulmonary metastasis in preclinical cancer models. The drug was developed primarily for advanced solid tumors and has been studied both alone and in combination with gemcitabine for advanced pancreatic carcinoma[1][4][6][7].
- Other names
- anti-PKN3 siRNA Atu027anti-PKN-3 siRNA Atu027anti-PKN 3 siRNA Atu027
02
Targets
PKN3 (Protein kinase N3)
Beyond the preview
Go deeper on Atu027.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atu027.